On 24 Sept 2026, CSPC PHARMA (01093.HK) said its Phase III trial of Becotatug (JMT101) plus osimertinib in EGFR ex20ins NSCLC met the primary endpoint.
On September 23, 2026, Hang Seng Indexes Company launched eight new indexes in a single day, including three in the Hang Seng TECH Composite Index series—the Hang Seng TECH Composite Index, the Hang Seng TECH Composite LargeCap Index and the Hang Seng TECH Composite MidSmallCap Index.
On 24 Sep 2026, UNITED LAB (03933.HK) said NMPA accepted the filing for its IDegLira once-daily diabetes shot, the first such biosimilar application in China.
On 24 Sep 2026, HANSOH PHARMA (03692.HK) said NMPA accepted the NDA for HS-20093, its B7-H3-targeting ADC, to treat osteosarcoma patients after 2+ prior lines.
On 24 Sep 2026, YH ENT (02306.HK) agreed to buy the remaining 46.55% of Yuhuatongxing for RMB 4mn, making it wholly-owned, and ended the Shenzhen Yiqi pact.
On 24 Sep 2026, GOLDENSOLAR (01121.HK) said its Dometic solar awning project entered field testing; cell efficiency verified at 28.2%; no supply contract yet.
On 24 Sep 2026, OCT (ASIA) (03366.HK) plans to sell 100% of OCT (Changshu) Investment by tender at a base price of at least RMB 90.45mn, a major transaction.
On September 24, Hong Kong stocks closed lower, with the HSI down 0.29%. DMALL led Stock Connect, up 15.62%, while southbound net buying was HK$2.900 billion.
The 9.65 million H shares held in aggregate by 12 cornerstone investors of COFOE MEDICAL (01187.HK) will see their lock-up period end on November 5, 2026, with the shares being released from lock-up from November 6, corresponding to a market value of approximately 380 million HKD based on the offer price. Institutions believe that, as a leading domestic home medical device company, the company's core products such as respiratory support, rehabilitation aids and hearing care are expected to contribute incremental growth in turn, with product mix optimization and a higher proportion of self-operated and self-manufactured products driving gross margin upward, while reliance on online platforms, intensifying industry competition and the progress of overseas expansion still warrant observation.
On 24 September 2026, HSBC HOLDINGS (00005.HK) said it granted 7,867,865 options to employees on 23 September under its UK savings plan at GBP 12.17 per share.
On September 24, 2026, Hong Kong stocks closed slightly lower, with the HSI down 0.29%. HORIZONROBOT-W rose 2.22% while GIGADEVICE fell 5.12% on the day.
On 24 September 2026, MEDTIDE (03880.HK) said it completed buying a Hangzhou site of about 30 mu for a peptide CDMO base with 3-5 tonne annual capacity.
on September 24, 2026, the three major Hong Kong indices opened lower and moved in a choppy range, with the Hang Seng Index down 0.29%, the Hang Seng TECH Index down 0.41%, and the Hang Seng China Enterprises Index down 0.09%.
On 24 September 2026, CSPC PHARMA (01093.HK) said the Phase III trial of its albumin-bound docetaxel HB1801 for advanced breast cancer has started in China.
On September 24, 2026, the HK shares ETFs market showed a defensive tilt. Dividend and high-dividend-yield products led the gains, with Ping An of China CSI HK Dividend ETF (03070.HK) up 1.04% to top the gainers list and six of the top ten gainers being dividend-related products. On the downside, Bosera SZSE ChiNext Daily (2x) Leveraged Product (07234.HK) fell 5.32% to lead the losers, while biotech, 5G, copper miners, gold miners and blockchain themes all dropped no less than 2.5%. Among southbound Stock Connect ETFs, dividend products edged higher while biotech led the declines, with CSOP Hang Seng Biotech ETF (03174.HK) down 2.50% at the top of the losers.
On September 24, 2026, DMALL rose 15.62% to top the gainers; Z.AI led liquidity with turnover of HKD 4.147 billion; NEW VISION CO released 2.4875 million shares from lock-up today.
